Ireland
--:--IST
Starting soon Not applicable

Lateral Versus Subcostal TAP Block for Drain-Site Analgesia in Laparoscopic Cholecystectomy

NCT07661576 · tracked via the Priya Life Science Turkey tracker
Sponsor
Turgut Ozal University
Phase
Not applicable
Started
2026-06-15
Last updated
2026-06-22

Condition(s) studied

Postoperative Pain After Laparoscopic Cholecystectomy

Investigational drug(s) / intervention(s)

Bilateral Subcostal TAP BlockLateral TAP Block Plus Contralateral Subcostal TAP Block

Bilateral Subcostal TAP Block: Ultrasound-guided bilateral subcostal transversus abdominis plane (TAP) block performed at the end of surgery prior to extubation. A total of 40 mL of 0.25% bupivacaine (20 mL per side) will be administered.

Lateral TAP Block Plus Contralateral Subcostal TAP Block: Ultrasound-guided lateral TAP block on the side of surgical drain placement combined with a contralateral subcostal TAP block. A total of 40 mL of 0.25% bupivacaine (20 mL at each injection site) will be administered.

Study summary

Laparoscopic cholecystectomy is a commonly performed surgical procedure. Despite its minimally invasive nature, patients may experience significant postoperative pain, particularly at trocar insertion sites and surgical drain entry sites. Pain originating from the drain site is often localized to the lateral abdominal wall and may contribute substantially to postoperative discomfort.

Transversus abdominis plane (TAP) block is a regional anesthesia technique widely used for postoperative pain management after abdominal surgery. Different TAP block approaches provide analgesia to different regions of the abdominal wall.

This prospective randomized clinical trial aims to compare two TAP block strategies in patients undergoing laparoscopic cholecystectomy with surgical drain placement. Patients will be randomly assigned to receive either bilateral subcostal TAP block or a targeted approach consisting of a lateral TAP block on the drain side and a subcostal TAP block on the opposite side.

The primary outcome is postoperative drain-site pain intensity measured using the Numeric Rating Scale (NRS) at 6 hours after surgery. Secondary outcomes include pain scores at additional postoperative time points, opioid consumption, time to first analgesic request, patient satisfaction, postoperative nausea and vomiting, sedation scores, and recovery parameters.

The findings of this study may help identify a more effective regional analgesia strategy for the management of drain-site pain following laparoscopic cholecystectomy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: Patients aged 18-75 years, classified as American Society of Anesthesiologists (ASA) physical status I-III, with a body mass index (BMI) \< 35 kg/m², undergoing elective laparoscopic cholecystectomy and requiring abdominal drain placement at the end of surgery. \- Exclusion Criteria:Patients with known allergy to local anesthetics, coagulopathy or ongoing anticoagulant therapy, infection at the planned block site, chronic opioid use, chronic pain syndromes, pregnancy, severe hepatic or renal insufficiency, inability to communicate effectively or to perform pain assessment using the Numeric Rating Scale (NRS), previous upper abdominal surgery, or drain placement outside the lateral abdominal wall (e.g., subxiphoid location) will be excluded. Patients who require conversion to open surgery, postoperative intensive care unit admission, or who experience block failure will also be excluded from the final analysis. \-

Primary outcome measure(s)

  • Drain-Site Pain Score at 6 Hours Postoperatively — 6 hours after surgery
    Pain intensity at the surgical drain insertion site measured using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain).

Trial sites (1)

FacilityCityRegionStatus
Malatya Training and Research Hospital Malatya Malatya
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07661576 on ClinicalTrials.gov ↗ ← All trials in Turkey